Fig. 3

Efficacy of combination therapy involving anti-PD-L1 treatment with either RT or PT. Tumors were treated with 3 × 8 Gy and anti-PD-L1 (10 mg/kg) 3 times per week over 3 weeks, 3 ten days after the injection of colon CT26 murine cancer cells into Balb/c mice (A) (Created in BioRender). Evaluation of untreated (black) CT26 tumors or those treated with anti-PD-L1 (blue), 3 × 8 Gy delivered with RT or PT irradiation combined with IgG (control) (orange) and RT or PT combined with anti-PD-L1 (purple) on tumor volumes implanted in immunocompetent BALB/c mice (B and D). Kaplan Meier survival curves with log-rank test comparisons, **p < 0.01 (C and E). Sample size: n = 5–10 mice per group for RT and n = 10–11 mice per group for PT. CR: complete response